99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer
暂无分享,去创建一个
M. Uder | B. Wullich | A. Cavallaro | P. Goebell | O. Prante | T. Kuwert | T. Bäuerle | C. Schmidkonz | P. Ritt | T. I. Goetz | D. Schmidt | M. Beck | J. Sanders | Julia Reinfelder | Claudia Hollweg
[1] T. Eade,et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study , 2018, The Journal of Nuclear Medicine.
[2] A. Maes,et al. Diagnostic sensitivity of Tc‐99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga‐68 PSMA PET/CT , 2017, The Prostate.
[3] A. Drzezga,et al. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[4] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.
[5] John Babich,et al. Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection , 2017, The Journal of Nuclear Medicine.
[6] Bernd J. Krause,et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Damien Bolton,et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.
[8] N. Lawrentschuk,et al. Updates of prostate cancer staging: Prostate-specific membrane antigen , 2016, Investigative and clinical urology.
[9] U. Haberkorn,et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[10] C. Stief,et al. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. , 2016, European urology.
[11] A. Buck,et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT , 2016, Clinical nuclear medicine.
[12] M. Schwaiger,et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[13] M. Schwaiger,et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. , 2016, The Journal of urology.
[14] Markus Schwaiger,et al. Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.
[15] R. Knuechel,et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[16] S. Houshmand,et al. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.
[17] D. Rubello,et al. 18F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[18] C. Nanni,et al. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT , 2015, Clinical nuclear medicine.
[19] Michael Lassmann,et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.
[20] S. Fanti,et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.
[21] A. García-Vicente,et al. Clinical utility of 18F‐fluorocholine positron‐emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study , 2015, BJU international.
[22] W. Horninger,et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[23] T. Kuwert,et al. Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis , 2015, EJNMMI Research.
[24] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[25] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[26] S. Vallabhajosula,et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer , 2014, The Journal of Nuclear Medicine.
[27] F. Fazio,et al. 11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy , 2014, The Journal of Nuclear Medicine.
[28] Dong Soo Lee,et al. Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology , 2014, Nuclear Medicine and Molecular Imaging.
[29] M. Loda,et al. Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[30] T. Holland-Letz,et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[31] W. Eckelman,et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[32] L. Bachmann,et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.
[33] S. Vallabhajosula,et al. 2200 A PHASE 1 PILOT STUDY OF 99MTC-MIP-1404 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)/CT IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY , 2013 .
[34] T. Holland-Letz,et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[35] W. Eckelman,et al. Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. , 2013, Bioorganic & medicinal chemistry letters.
[36] D. Hörsch,et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Joachim Hornegger,et al. Absolute quantification in SPECT , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[38] Joachim Hornegger,et al. Quantitative Accuracy of Clinical 99mTc SPECT/CT Using Ordered-Subset Expectation Maximization with 3-Dimensional Resolution Recovery, Attenuation, and Scatter Correction , 2010, Journal of Nuclear Medicine.
[39] P. Waldenberger,et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.
[40] V. Bettinardi,et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[41] C. Ganter,et al. Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging , 2010, Investigative radiology.
[42] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[43] P. Nelson,et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.
[44] V. Canzonieri,et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[45] J. Quian,et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.
[46] Prabhjot Kaur,et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] S. A. Wolfe,et al. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. , 2002, Gene.
[48] P. Schellhammer,et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.
[49] M. Uder,et al. First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer , 2017, Clinical nuclear medicine.
[50] U. Haberkorn,et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[51] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.